# Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors

> **NCT04126070** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Xiao X. Wei, MD** · enrollment: 60 (estimated)

## Conditions studied

- Hormone Sensitive Prostate Cancer
- Prostate Adenocarcinoma
- Metastasis Prostate Adenocarcinoma

## Interventions

- **DRUG:** Androgen Deprivation Therapy
- **DRUG:** Nivolumab
- **DRUG:** Docetaxel

## Key facts

- **NCT ID:** NCT04126070
- **Lead sponsor:** Xiao X. Wei, MD
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2020-05-11
- **Primary completion:** 2025-07-29
- **Final completion:** 2026-06-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04126070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04126070, "Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors". Retrieved via MORVS 2026-10-14 from https://api.morvs.ai/clinical/NCT04126070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*